Epithalon vs FOXO4-DRI
A side-by-side research comparison of Epithalon and FOXO4-DRI across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Epithalon | FOXO4-DRI |
|---|---|---|
| Full name | Epithalon (Epitalon / Epithalone) | FOXO4-D-Retro-Inverso Peptide (Senolytic) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Activates telomerase reverse transcriptase (hTERT) expression for telomere maintenance. Also normalizes circadian rhythm via melatonin regulation and modulates antioxidant enzymes. | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. |
| Molecular weight | 390.4 Da | ~4,500 Da |
| Half-life | 3-4 hours | 12-24 hours (D-amino acid stability) |
| Bioavailability | High (SubQ) | Moderate (SubQ) |
| Typical dose | 5-10 mg | 5-10 mg/kg (animal studies) |
| Frequency | Daily for 10-20 days | 3x per week for 3 weeks |
| Route | Subcutaneous injection | Subcutaneous |
Epithalon reported benefits
- Telomerase activation
- Telomere lengthening
- Melatonin normalization
- Improved sleep patterns
- Antioxidant enzyme upregulation
- Potential lifespan extension
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Related comparisons
Research and educational reference only. Not medical advice.